Nikkhah H, Golalipour M, Doozandeh A, et al. - Researchers conducted this randomized clinical trial to assess the impact of systemic erythropoietin, as well as oral steroids, in the management of recent-onset non-arteritic anterior ischemic optic neuropathy (NAION). In group A (systemic erythropoietin), group B (oral steroids), and group C (control), patients diagnosed with NAION within 5 days were randomized. Group A received 10,000 units of erythropoietin twice a day for 3 days and group B received oral prednisone 75 mg daily tapered off in 6 weeks. Data reported that 55% of patients in group A vs 34.3% in group B and 31.2% in group C had an improvement of at least 3 lines in the best-corrected visual acuity values at the 6th month of follow-up visit. The findings suggest the beneficial effects of systemic erythropoietin in preserving optic nerve function and structure in recent-onset NAION.